Table 2.
Safety outcomes of patients with remdesivir administration after propensity score matching analysis.
| Outcomes | eGFR < 30 mL/min (n = 23) |
eGFR ≥ 30 mL/min (n = 23) |
p Value |
|---|---|---|---|
| 30-days mortality (%) | 13.0 (3/23) | 13.0 (3/23) | 1.00 a |
| Acute kidney injury (%) | 0 (0/23) | 4.3 (1/23) | 1.00 a |
| Liver function disorder | 8.7 (2/23) | 4.3 (1/23) | 1.00 a |
| AST elevation | 2 | 1 | |
| ALT elevation | 0 | 0 | |
| Others | |||
| Hyperglycemia | 21.3 (5/23) | 21.3 (5/23) | 1.00 a |
| Anemia | 8.7 (2/23) | 4.3 (1/23) | 1.00 a |
| Thrombocytopenia | 4.3 (1/23) | 8.7 (2/23) | 1.00 a |
a Fisher’s exact test. eGFR: estimated glomerular filtration rate; AST: aspartate aminotransferase; ALT: alanine transaminase.